Kadcyla for advanced HER2-positive breast cancer, approved in EU
Roche has announced that Kadcyla ( Trastuzumab emtansine or T-DM1 ) has been approved by the European Commission for people with previously treated HER2-positive advanced breast cancer.
Specifically, ...
read article